Bone Biologics Corp Stock Probability of Future Stock Price Finishing Over 1.31
BBLG Stock | USD 1.31 0.06 4.80% |
Bone |
Bone Biologics Target Price Odds to finish over 1.31
The tendency of Bone Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
1.31 | 90 days | 1.31 | about 75.63 |
Based on a normal probability distribution, the odds of Bone Biologics to move above the current price in 90 days from now is about 75.63 (This Bone Biologics Corp probability density function shows the probability of Bone Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.53 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bone Biologics will likely underperform. Additionally Bone Biologics Corp has an alpha of 0.7684, implying that it can generate a 0.77 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bone Biologics Price Density |
Price |
Predictive Modules for Bone Biologics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bone Biologics Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bone Biologics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bone Biologics is not an exception. The market had few large corrections towards the Bone Biologics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bone Biologics Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bone Biologics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.77 | |
β | Beta against Dow Jones | 1.53 | |
σ | Overall volatility | 0.36 | |
Ir | Information ratio | 0.04 |
Bone Biologics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bone Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bone Biologics Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.Bone Biologics Corp is way too risky over 90 days horizon | |
Bone Biologics Corp may become a speculative penny stock | |
Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
Bone Biologics Corp has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
Bone Biologics Corp has a frail financial position based on the latest SEC disclosures |
Bone Biologics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bone Stock often depends not only on the future outlook of the current and potential Bone Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bone Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 263.1 K | |
Cash And Short Term Investments | 3 M |
Bone Biologics Technical Analysis
Bone Biologics' future price can be derived by breaking down and analyzing its technical indicators over time. Bone Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Bone Biologics Corp. In general, you should focus on analyzing Bone Stock price patterns and their correlations with different microeconomic environments and drivers.
Bone Biologics Predictive Forecast Models
Bone Biologics' time-series forecasting models is one of many Bone Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Bone Biologics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Bone Biologics Corp
Checking the ongoing alerts about Bone Biologics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bone Biologics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Bone Biologics Corp is way too risky over 90 days horizon | |
Bone Biologics Corp may become a speculative penny stock | |
Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
Bone Biologics Corp has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
Bone Biologics Corp has a frail financial position based on the latest SEC disclosures |
Check out Bone Biologics Backtesting, Bone Biologics Valuation, Bone Biologics Correlation, Bone Biologics Hype Analysis, Bone Biologics Volatility, Bone Biologics History as well as Bone Biologics Performance. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.